Reference summary — not medical advice or a personal risk estimate.
Diabetes drug (pioglitazone)
Type-2 diabetes drug; IARC Group 2A due to bladder-cancer signal in long-term users.
Also known as: pioglitazone
What this does NOT mean
Finding a factor documented in this product category does not establish that ordinary use of diabetes drug (pioglitazone) causes cancer. It means research — through regulatory testing, recall records, or IARC review — has found that chemical present in this category. Whether it matters for you depends on formulation, dose, frequency, and route of exposure.
What has been documented
- PioglitazoneIARC Group 2AIARC Group 2AExposure from · high confidence
Direct IARC Group 2A classification (bladder cancer signal).
Evidence source: IARC
How to read this page
A factor appearing on this page means it has been documented in this product category — through EPA / FDA testing, IARC monographs, or regulatory recall records. Whether it presents a meaningful personal risk depends on the specific formulation, dose, and how you're exposed. Click any factor to read what science actually says about it, and where.